科伦博泰生物-B(06990)发布公告galagaarcadegame,该公司的主要产品A400(EP0031)(在转染过程中重排(RET)小分子激酶抑制剂项目,亦称为KL590586或EP0031)获得了美国食品药品监督管理局(FDA)批准进入2期临床开发。
A400(EP0031)是第二代选择性RET抑制剂(SRI),对常见的RET基因融合和突变具有广泛活性。
本文作者:editor@邮箱
版权声明 : 除非注明,本文由 editor 原创编译
转载请注明出处: http://www.xpj5229.com/Entrepreneurship/1870.html
fishingglasses| Egg market analysis: National stocks increased year-on-year, spot prices bottomed out expectations and May Day impact
damquick3sls8000fd| The education sector of China General Education is on the rise, rising by more than 7%
nintendoswitchgamescrashbandicoot| HSBC: The Swiss franc has overperformed this year and is bearish on the British pound against the Swiss franc
freespinny| Set up the audience! Just now, big news came from the stock market!